sorafenib has been researched along with Astrocytoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A | 1 |
| Amos, S; Hussaini, IM; Kirzner, J; Sherman, JH; Siu, A | 1 |
| Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 1 |
| Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D | 1 |
| de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW | 1 |
2 trial(s) available for sorafenib and Astrocytoma
| Article | Year |
|---|---|
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Ventriculoperitoneal Shunt | 2014 |
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
4 other study(ies) available for sorafenib and Astrocytoma
| Article | Year |
|---|---|
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Temozolomide | 2017 |
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.
Topics: Astrocytoma; Blotting, Western; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; Sorafenib | 2014 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combination; Glioblastoma; Glioma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Necrosis; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2014 |
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib | 2015 |